Nexus Pharmaceuticals Inc., a woman-owned, privately held, US-based healthcare company, announced recently an agreement with the village of Pleasant Prairie, Wisconsin to build an industry-leading sterile injectable manufacturing facility. The company, which specializes in developing innovative processes to manufacture specialty and generic injectable drugs, is investing in a facility that will support the production and supply of injectable drugs in an array of therapeutic areas including anesthesia, oncology, cardiovascular and neurology.
"This investment is needed to drive the continued growth for the U.S. pharmaceutical manufacturing industry," said Mariam Darsot, Chief Executive Officer. "We would like to thank the Wisconsin Economic Development Corporation, The Milwaukee 7, Kenosha Area Business Alliance and The Village of Pleasant Prairie for their support as we develop our plans for this major expansion project."
The multi-phase, multi-year project is expected to be completed in ten years, with an estimated investment of $250M. Construction is planned to commence in August 2019 and is expected to be completed in 2021 for the first phase. After the facility and manufacturing processes are approved by the Food and Drug Administration (FDA), commercial production is expected to commence in 2022.
"This is one of the most significant pharmaceutical investments in Wisconsin in years," said Governor Tony Evers.
The initial phase 1 investment of $85M will support a new, three-story manufacturing facility with cutting-edge technology including an advanced isolator system for maximum product protection and sterility; reducing the risk of contamination. The facility will also include multiple lyophilization (freeze-drying) machines to support production of Nexus' current portfolio and robust pipeline of generic and specialty injectable drugs.
"The Village is honored to welcome Nexus Pharmaceuticals to Southeastern Wisconsin," said Village Board Chair Steinbrink. "Nexus is a remarkable company with excellent jobs, strong growth and high values. I am confident that Nexus will find Prairie Highlands Corporate Park in Pleasant Prairie to be an exceptional location to grow their business."
The new 100,000 square foot facility is being designed by Integrated Project Services (IPS) with construction management services being provided by Turner Construction, both of whom have strong backgrounds in design and construction of pharmaceutical manufacturing. The facility will support the Wisconsin economy by creating 77 new jobs in fields of high-tech manufacturing and science by 2022.
"As a pharmaceutical company with a significant focus on sterile injectable medicines, Nexus Pharmaceuticals understands the growing patient demand for high quality and accessible generic injections," said Shahid Ahmed, Chief Scientific Officer. "With the addition of our new manufacturing facility, we are committed to providing a more stable and reliable supply of sterile injectables–a category that is particularly susceptible to drug shortages."
The Nexus Pharmaceuticals team has combined their expertise in drug development with advanced technological manufacturing equipment to mitigate drug shortages that have plagued the market for years of critical-need, life-saving sterile injectable medications. "We believe in America's future in manufacturing and, to support our mission, we will need engineers, scientists, and technicians joining together to lead and collaborate," said John Cook, Vice President of Manufacturing. "Our new facility will employ individuals who demonstrate integrity in their actions and who will work to deliver high-quality medications that physicians, pharmacists and nurses rely on every day in the U.S. to treat and save their patients' lives."
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they're needed most.